Table 2.
Comparison of clinical characteristics of patients who were HIV negative and HIV positive and infected with T. marneffei
| Variables | All, n (%) | HIV negative | HIV positive | p |
|---|---|---|---|---|
| (n = 143) | (n = 98) | |||
| Sex (male) | 178 (73.9) | 95 (66.4) | 83 (84.7) | < 0.01 |
| Age (≥ 63 years) | 42 (17.4) | 34 (23.8) | 8 (8.2) | < 0.01 |
| Residence (rural) | 75 (31.1) | 51 (35.7) | 24 (24.5) | 0.09 |
| Smoking history | 84 (34.9) | 48 (33.6) | 36 (36.7) | 0.71 |
| Lymph node enlargement | 194 (80.5) | 121 (84.6) | 73 (74.5) | 0.07 |
| Hepatosplenomegaly | 82 (34.0) | 45 (31.5) | 37 (37.8) | 0.38 |
| Skin lesion | 141 (58.5) | 84 (58.7) | 57 (58.2) | 1.00 |
| Chest involvement# | 229 (95.0) | 140 (97.9) | 89 (90.8) | 0.03 |
| Bone destruction | 61 (25.3) | 60 (42.0) | 1 (1.0) | < 0.01 |
| Underlying diseases* | 42 (17.4) | 37 (25.9) | 5 (5.1) | < 0.01 |
| Hemoglobin (≥ 94.1 g/L) | 110 (45.6) | 62 (43.4) | 48 (49.0) | 0.47 |
| Neutrophil (≥ 15.3 × 109/L) | 52 (21.6) | 51 (35.7) | 1 (1.0) | < 0.01 |
| Lymphocyte (≥ 0.19 × 109/L) | 221 (91.7) | 141 (98.6) | 80 (81.6) | < 0.01 |
| Prothrombin time (≥ 15.6 s) | 39 (16.2) | 28 (19.6) | 11 (11.2) | 0.12 |
| Oxygen therapy | 130 (53.9) | 99 (69.2) | 31 (31.6) | < 0.01 |
| Admission to ICU | 18 (7.5) | 17 (11.9) | 1 (1.0) | < 0.01 |
| Antifungal therapy | ||||
| Triazoles† alone | 75 (31.1) | 55 (38.5) | 20 (20.4) | 0.01 |
| AMB + triazoles | 141 (58.5) | 76 (53.1) | 65 (66.3) | |
| Others†† | 25 (10.4) | 12 (8.4) | 13 (13.3) |
HIV human immunodeficiency virus, ICU intensive care unit, AMB amphotericin B
#Chest involvement included pulmonary lesions, pleural effusion, and hydropericardium
*Underlying diseases included diabetes, chronic kidney disease, malignant tumors, autoimmune diseases, and post-transplant
†Triazoles included fluconazole, itraconazole, and voriconazole
††Others included caspofungin, 5-flucytosine, and micafungin